AstraZeneca PLC (AZN)vsCandel Therapeutics Inc (CADL)
AZN
AstraZeneca PLC
$161.42
+0.88%
HEALTHCARE · Cap: $263.09B
CADL
Candel Therapeutics Inc
$10.59
+0.09%
HEALTHCARE · Cap: $766.41M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 197954745% more annual revenue ($61.37B vs $31,000). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CADL
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.42
$35.51 discount
Intrinsic value data unavailable for CADL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : CADL
The strongest argument for CADL centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : CADL
The primary concerns for CADL are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while CADL is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 22/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Candel Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets and destroys cancer cells while preserving healthy tissue. The company has developed a promising pipeline that addresses several challenging malignancies, enhancing the body’s immune response against tumors and striving for significant advancements in therapeutic efficacy. With a solid intellectual property foundation and strategic collaborations with leading research institutions, Candel is well-positioned to be at the forefront of groundbreaking innovations in oncology, with the ultimate goal of improving patient outcomes and reshaping cancer care standards.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?